Trial Profile

Vaccine Responses in Patients With B Cell Malignancies

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 05 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adjuvanted Hepatitis-B vaccine (Recombinant)-Dynavax (Primary) ; Elasomeran (Primary) ; GSK 137173A (Primary) ; GSK 1536489A (Primary) ; Influenza vaccine (Optaflu) (Primary) ; Influenza virus vaccine (Primary) ; Influenza virus vaccine (Afluria) (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal 23-valent vaccine Walvax Biotechnology (Primary) ; Tozinameran (Primary)
Indications COVID 2019 infections; Hepatitis B; Herpes zoster; Influenza virus infections; Pneumococcal infections
Focus Pharmacodynamics

Most Recent Events

27 Aug 2024 Planned End Date changed from 16 Aug 2024 to 16 Aug 2025.
27 Aug 2024 Planned primary completion date changed from 16 Aug 2024 to 16 Aug 2025.
22 Aug 2023 Planned primary completion date changed from 9 Aug 2023 to 16 Aug 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com